Literature DB >> 9404252

Age dependent efficacy of implantable cardioverter-defibrillator treatment: observations in 450 patients over an 11 year period.

H J Trappe1, P Pfitzner, M Achtelik, H G Fieguth.   

Abstract

OBJECTIVE: To determine whether implantable cardioverter-defibrillator (ICD) treatment is beneficial in elderly patients with life threatening ventricular tachyarrhythmias.
DESIGN: Since January 1984, ICDs were implanted in 450 patients to evaluate surgical risk, complications and mean survival in relation to patient age; 81 patients (18%) were < or = 50 years at the time of ICD implant, 254 patients (56%) were between 51 and 64 years, and the remaining 115 (26%) were > or = 65 years. Epicardial lead systems were implanted in 209 patients (46%), while transvenous lead systems were implanted in 241 (54%).
RESULTS: 13 patients (3%) died perioperatively, more often after epicardial (11 of 209 patients, 5%) than after transvenous ICD implantation (one of 241 patients, < 1%) (p < 0.05). During a mean (SD) follow up of 28 (24) months (range < 1 to 114 months), 90 patients (20%) died. Of these, nine (2%) died from sudden arrhythmic death; five (1%) died suddenly, probably as a result of non-arrhythmic causes; 55 (12%) died from other cardiac causes (congestive heart failure, myocardial infarction); and 21 (5%) died from non-cardiac causes. The three, five, and seven year survival for arrhythmic mortality was 95% in patients < or = 50 years compared with a three year survival of 93% and a five and seven year survival of 91% in patients of 51 to 64 years, and a three, five, and seven year survival of 99% in patients > or = 65 years. 362 patients (80%) received ICD discharges (21 (43) shocks per patient), with a similar incidence among all three patient groups (< or = 50 years, 80%; 51 to 64 years, 81%; > or = 65 years, 79%). The time interval between ICD implant and the first ICD treatment was shorter in patients > or = 65 years (8 (8) months) than in patients between 51 and 64 years (11 (14) months) or < or = 50 years (11 (11) months) (p < 0.05). Survival time following first appropriate shock was 30 (24) months in patients < or = 50 years, 30 (26) months in patients of 51 to 64 years, and 19 (20) months in patients > or = 65 years.
CONCLUSIONS: Elderly patients benefit from ICD treatment, and survive for a considerable time after the first treatment. Therefore, elderly patients should be considered candidates for ICD implantation if life threatening ventricular tachy-arrhythmias are present.

Entities:  

Mesh:

Year:  1997        PMID: 9404252      PMCID: PMC1892255     

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  29 in total

1.  Prospective antiarrhythmic studies assessing prophylactic pharmacological and device therapy in high risk coronary patients.

Authors:  A J Moss
Journal:  Pacing Clin Electrophysiol       Date:  1992-04       Impact factor: 1.976

2.  The automatic implantable cardioverter-defibrillator: efficacy, complications and survival in patients with malignant ventricular arrhythmias.

Authors:  P A Kelly; D S Cannom; H Garan; G S Mirabal; J W Harthorne; R J Hurvitz; G J Vlahakes; M L Jacobs; J P Ilvento; M J Buckley
Journal:  J Am Coll Cardiol       Date:  1988-06       Impact factor: 24.094

3.  Survival in patients with depressed left ventricular function treated by implantable cardioverter defibrillator.

Authors:  K Axtell; P Tchou; M Akhtar
Journal:  Pacing Clin Electrophysiol       Date:  1991-02       Impact factor: 1.976

4.  Initial experience with a new transvenous defibrillation system.

Authors:  H J Trappe; H Klein; H G Fieguth; B Kielblock; P Wenzlaff; P R Lichtlen
Journal:  Pacing Clin Electrophysiol       Date:  1993-01       Impact factor: 1.976

Review 5.  Implantable cardioverter defibrillator for prevention of sudden cardiac death in patients with ventricular tachycardia and ventricular fibrillation: ICD therapy in sudden cardiac death.

Authors:  M Akhtar; M Jazayeri; J Sra; P Tchou; K Rovang; Z Blanck; A Dhala; S Deshpande; K Axtell
Journal:  Pacing Clin Electrophysiol       Date:  1993-03       Impact factor: 1.976

6.  Electrophysiological laboratory, electrophysiologist-implanted, nonthoracotomy-implantable cardioverter/defibrillators.

Authors:  A P Fitzpatrick; M D Lesh; L M Epstein; R J Lee; A Siu; S Merrick; J C Griffin; M M Scheinman
Journal:  Circulation       Date:  1994-06       Impact factor: 29.690

7.  Implantable transvenous cardioverter-defibrillators.

Authors:  G H Bardy; B Hofer; G Johnson; P J Kudenchuk; J E Poole; G L Dolack; M Gleva; R Mitchell; D Kelso
Journal:  Circulation       Date:  1993-04       Impact factor: 29.690

8.  Time to first shock and clinical outcome in patients receiving an automatic implantable cardioverter-defibrillator.

Authors:  R J Myerburg; R M Luceri; R Thurer; D K Cooper; L Zaman; A Interian; P Fernandez; M Cox; F Glicksman; A Castellanos
Journal:  J Am Coll Cardiol       Date:  1989-08       Impact factor: 24.094

9.  Sudden coronary death in the United States: 1980-1985.

Authors:  R F Gillum
Journal:  Circulation       Date:  1989-04       Impact factor: 29.690

10.  Role of antitachycardia pacing in patients with third generation cardioverter defibrillators.

Authors:  H J Trappe; H Klein; B Kielblock
Journal:  Pacing Clin Electrophysiol       Date:  1994-03       Impact factor: 1.976

View more
  3 in total

1.  Subject of the year: who are we missing, who are we overtreating, and who is best served? Refining the prescription of implantable cardioverter-defibrillator therapy.

Authors:  Andrew E Epstein
Journal:  J Interv Card Electrophysiol       Date:  2009-11       Impact factor: 1.900

2.  Impact of advanced age on survival in patients with implantable cardioverter defibrillators.

Authors:  Cara N Pellegrini; Keane Lee; Jeffrey E Olgin; Mintu P Turakhia; Zian H Tseng; Randall Lee; Nitish Badhwar; Byron Lee; Paul D Varosy
Journal:  Europace       Date:  2008-09-24       Impact factor: 5.214

Review 3.  Causes and prevention of sudden cardiac death in the elderly.

Authors:  Patricia Tung; Christine M Albert
Journal:  Nat Rev Cardiol       Date:  2013-01-29       Impact factor: 32.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.